Vimarsana
Biggest News Aggregation in the World

Page 5 - Equal Life News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Equal Life. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Equal Life Today - Breaking & Trending Today

Diabetes management: Taking back quality of life - Vimarsana News

Diabetes management: Taking back quality of life

People with diabetes may experience an array of emotions as they manage their condition, but improving nutrition is one area within their control that can have a positive impact on their quality of life.

Impact on treatment decisions with schizophrenia - Vimarsana News

Impact on treatment decisions with schizophrenia

Healthcare providers’ usage of a dashboard that provided medication ingestion information impacted treatment decisions and clinical assessments.

Global Blood Therapeutics, Inc.: MHRA Grants Marketing Authorization for GBT's Oxbryta (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older - Vimarsana News

Global Blood Therapeutics, Inc.: MHRA Grants Marketing Authorization for GBT's Oxbryta (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell diseaseSOUTH SAN FRANCISCO, Calif., July

Astellas Submits Fezolinetant New Drug Application to U.S. FDA - Vimarsana News

Astellas Submits Fezolinetant New Drug Application to U.S. FDA

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced a New Drug Application (NDA) for...

Astellas to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1™ Trial of Fezolinetant in Oral Session at the American College of Obstetricians and Gynecologists Annual Meeting - Vimarsana News

Astellas to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1™ Trial of Fezolinetant in Oral Session at the American College of Obstetricians and Gynecologists Annual Meeting

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will present 12-week results from the pivotal Phase 3...